The shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) currently has mean rating of 1.40 while 3 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and Zero recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending Jun-16 is 61.90 million by 5 analysts. The means estimate of sales for the year ending Dec-16 is 258.42 million by 5 analysts.
The mean price target for the shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is at 18.00 while the highest price target suggested by the analysts is 20.00 and low price target is 16.00. The mean price target is calculated keeping in view the consensus of 4 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) stands at 0.01 while the EPS for the current year is fixed at 0.11 by 4 analysts.
The next one year’s EPS estimate is set at 0.64 by 4 analysts while a year ago the analysts suggested the company’s EPS at 0.11. The analysts also projected the company’s long-term growth at 25.00% for the upcoming five years.
In its latest quarter ended on 31st March 2016, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) reported earnings of $0.12. The posted earnings topped the analyst’s consensus by $0.15 with the surprise factor of 500.00%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The companys product portfolio comprises Enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients presumed with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and Lidocaine jelly, a local anesthetic product used primarily for urological procedures. It also provides Lidocaine topical solution, a local anesthetic for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, lidocaine, naloxone, and sodium bicarbonate for emergency use in hospital settings; and epinephrine in vial form; and lorazepam injection, a sedative for surgery and medical procedures. In addition, the company develops Primatene Mist HFA, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma; and active pharmaceutical ingredients, such as recombinant human insulin and porcine insulin. Further, it has a pipeline of 21 generic and proprietary product candidates in various stages of development for various indications. The companys products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was established in 1996 and is headquartered in Rancho Cucamonga, California.